Botulism News and Research

RSS
Botulism is a rare but serious paralytic illness caused by botulinum toxin, which is produced by the bacterium ''Clostridium botulinum''. The toxin enters the body in one of four ways: by colonization of the digestive tract by the bacterium in children (infant botulism) or adults (adult intestinal toxemia), by ingestion of toxin from foodstuffs (foodborne botulism) or by contamination of a wound by the bacterium (wound botulism).
Cangene extends botulism antitoxin contract with BARDA

Cangene extends botulism antitoxin contract with BARDA

Cangene receives European Commission approval to market ImmunoGam

Cangene receives European Commission approval to market ImmunoGam

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

New strategy against Botulinum toxin

New strategy against Botulinum toxin

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Three-day interactive conference to showcase new trendsetting techniques and research in aesthetic plastic surgery

Three-day interactive conference to showcase new trendsetting techniques and research in aesthetic plastic surgery

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene to acquire U.S. commercialization rights for HepaGam B

Roundtable discussion to elevate awareness about the importance of biopreparedness

Roundtable discussion to elevate awareness about the importance of biopreparedness

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

Neogen announces first-quarter results of fiscal 2010

Neogen announces first-quarter results of fiscal 2010

New discovery on how botulism paralyzes nerve cells

New discovery on how botulism paralyzes nerve cells

DNA biosynthesis discovery could lead to better antibiotics

DNA biosynthesis discovery could lead to better antibiotics

Discovery of new chemical reaction for DNA production in bacteria and viruses

Discovery of new chemical reaction for DNA production in bacteria and viruses

New nasal spray vaccine shown to be effective against botulism

New nasal spray vaccine shown to be effective against botulism

Scientists determine drug target for the most potent botulinum neurotoxin

Scientists determine drug target for the most potent botulinum neurotoxin